Sodium polystyrene sulfonate, sold under brand names like Kayexalate, is a cation-exchange resin prescribed to lower dangerously high potassium levels in the blood. It has been in clinical use since the 1950s, making it one of the oldest drugs still used for hyperkalemia, yet its evidence base is remarkably thin. Two small clinical trials form the core of its efficacy data, and much of what clinicians know about its risks comes from case reports and retrospective studies rather than large randomized trials.1PubMed Central. Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review Despite that, it remains widely prescribed, in part because it is extremely cheap compared to newer alternatives.
How It Lowers Potassium
SPS is a synthetic polymer that works through ion exchange. When you swallow it (or when it is given rectally), the resin travels through the gastrointestinal tract without being absorbed into the bloodstream. Along the way, it releases sodium ions and picks up potassium ions, which are then carried out of the body in stool. The exchange happens primarily in the large intestine, where the contact time between the resin and the gut contents is longest.2Chemical and Pharmaceutical Bulletin. Fundamental Investigation of Adsorption Behavior onto Sodium Polystyrene Sulfonate to Potassium Ions and Its Concomitant Drugs in the Digestive Tract
The process is straightforward in principle but slow in practice. SPS is not a rapid-acting treatment. In acute hyperkalemia, its onset of action runs around six hours, which is far too slow to address a cardiac emergency.3PubMed Central. Comparison of Patiromer to Sodium Polystyrene Sulfonate in Acute Hyperkalemia For an immediately life-threatening potassium spike, clinicians rely on intravenous calcium to stabilize the heart, insulin with glucose to shift potassium into cells, and sometimes dialysis. SPS sits in a slower lane, sometimes used afterward to keep potassium from rebounding once those faster interventions wear off.
How Much It Actually Lowers Potassium
Typical dosing in adults ranges from 15 to 60 grams by mouth, with the specific dose adjusted to how high the potassium reading is. One institution’s dosing guideline recommended 30 grams when potassium was above 5 but below 6 mEq/L, and 60 grams when it was 6 or higher.4Hospital Pharmacy. Sodium Polystyrene Sulfonate Dosing Guidelines for the Treatment of Adult Hyperkalemia In practice, the potassium drop after a single dose tends to be modest. A retrospective study of acute hyperkalemia cases found an average reduction of less than 1 mEq/L.5PubMed. Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study
A systematic review looking at polystyrene sulfonate resins in hyperkalemia concluded that the most credible evidence for any benefit applies to chronic, not acute, hyperkalemia. For acute situations, the review found no high-quality evidence supporting use.6PubMed. Polysulfonate Resins in Hyperkalemia: A Systematic Review That distinction matters. A patient on dialysis who chronically runs high potassium between sessions occupies a very different clinical scenario from someone whose potassium spiked in the emergency department due to kidney failure or a medication reaction.
The Gastrointestinal Safety Problem
The most alarming risk linked to SPS is intestinal necrosis, a condition where tissue in the bowel wall dies. This can be life-threatening. Early concern focused on formulations that combined SPS with sorbitol, a sugar alcohol added to counteract the constipation SPS often causes. A review of cases at one institution identified 11 patients with confirmed intestinal ischemia temporally linked to SPS-sorbitol. In that group, the average age was about 71, and the damage ranged from focal ulceration to full-thickness destruction of the bowel wall.7PubMed Central. Intestinal Necrosis due to Sodium Polystyrene Sulfonate (Kayexalate) in Sorbitol
A broader systematic review of published case reports tallied 58 cases of serious gastrointestinal injury. The colon was the most common site of damage, involved in about three-quarters of cases. Transmural necrosis, where the injury extends through the entire thickness of the bowel wall, was the most frequent finding. About a third of those 58 patients died from their gastrointestinal injury.8Elsevier / The American Journal of Medicine. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review
For decades, the sorbitol component took much of the blame. In 2009, the U.S. FDA issued a warning against concomitant use of SPS and sorbitol. But necrosis has also been reported with sorbitol-free SPS preparations, which has shifted attention back to the resin itself. Under a microscope, SPS crystals can be identified embedded in damaged tissue, forming distinct concretions in the gastrointestinal tract.9PubMed Central. Histopathological lesions of the gastrointestinal tract associated with the use of polystyrene sulfonate and sevelamer: a meta-analysis
How Common Is Serious GI Harm
Case reports make intestinal necrosis sound terrifying, and it is for those affected. But how often does it happen? A meta-analysis pooling data from over 26,000 patients treated with SPS found that the overall odds of intestinal necrosis were not statistically elevated compared to controls, though the numbers trended higher. The pooled odds ratio was about 1.4, but the confidence interval was wide and crossed 1, meaning the data could not confirm a clear increase.10PubMed. Risk of Intestinal Necrosis With Sodium Polystyrene Sulfonate: A Systematic Review and Meta-analysis When the analysis broadened to include all severe gastrointestinal events (not just necrosis), the risk was more clearly elevated, with a pooled hazard ratio of about 1.5 that reached statistical significance.
A large study of older adults provided a sharper picture. Among patients of advanced age, SPS use was associated with roughly double the risk of hospitalization for a serious gastrointestinal event within the next 30 days compared to matched nonusers. Intestinal ischemia and thrombosis were the most common injuries.11JAMA Internal Medicine. Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age In absolute terms, the events were uncommon, roughly 2 per thousand per year versus 1 per thousand, but for a drug whose efficacy evidence is shaky to begin with, even a small absolute increase in a deadly complication invites scrutiny.
Sodium Loading and Fluid Overload
Because SPS exchanges potassium for sodium, every dose delivers a significant sodium load. For patients with heart failure, advanced kidney disease, or poorly controlled blood pressure, extra sodium is the last thing the body needs. The absorbed sodium can promote fluid retention, potentially worsening edema and raising blood pressure. Studies in pre-dialysis patients have documented increases in both serum sodium and atrial natriuretic peptide (a hormone released when the heart is stretched by excess fluid) after SPS use, signals of volume expansion that did not appear with the calcium form of polystyrene sulfonate.12PubMed. Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia
This sodium issue has led some nephrologists to argue that SPS should not be used at all. An editorial in a kidney journal explicitly called SPS “unsafe” and argued it should not be prescribed for hyperkalemia, citing both the gastrointestinal risks and the fluid-overload concern.13PubMed Central. Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere ! That position remains a minority view in formal guidelines, but it reflects genuine frustration among clinicians who feel the drug has persisted on formularies more out of habit than evidence.
The calcium form of polystyrene sulfonate (CPS), which swaps calcium for potassium instead of sodium, avoids the sodium-loading problem. It is used in some countries as an alternative. One comparison between the two forms in chronic kidney disease patients noted that diastolic blood pressure increased with SPS but not with CPS.14Journal of Ayub Medical College, Abbottabad. TREATMENT OF HYPERKALEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A COMPARISON OF CALCIUM POLYSTYRENE SULPHONATE AND SODIUM POLYSTYRENE SULPHONATE CPS has its own risks, though, including hypercalcemia in patients who already have high calcium levels, a common issue in kidney disease.
Off-Target Electrolyte Effects
SPS does not bind potassium exclusively. It can also pull calcium and magnesium out of the gut, and the exchange process can shift the body’s acid-base balance. Case reports have documented children developing acute drops in calcium levels (hypocalcemia) and worsening metabolic alkalosis shortly after starting SPS therapy. In both reported pediatric cases, the hypocalcemia was caught on routine lab work and corrected by stopping SPS and giving oral calcium supplements.15PubMed Central. Acute Hypocalcemia and Metabolic Alkalosis in Children on Cation-Exchange Resin Therapy The practical lesson is that patients on SPS need monitoring of more than just potassium. Calcium, magnesium, and bicarbonate levels all warrant attention, especially in the first days of treatment.
Neonates are particularly vulnerable to electrolyte swings from SPS. Two extremely low birth weight infants treated with SPS for hyperkalemia developed severe hypernatremia, a dangerous rise in blood sodium, that had not been described before in that population.16PubMed. Hypernatraemia induced by sodium polystyrene sulphonate (Kayexalate) in two extremely low birth weight newborns Tiny bodies with immature kidneys cannot clear the sodium load the way an adult can, making SPS use in neonates a high-wire act even when potassium levels need urgent attention.
Drug Interactions
A resin that binds positively charged ions in the gut does not discriminate perfectly between potassium and other substances passing through. SPS can bind medications taken around the same time, reducing how much of those drugs the body actually absorbs. The binding happens through two pathways: ionic interactions (where a positively charged drug is attracted to the negatively charged resin) and hydrophobic interactions (where water-repelling parts of a drug stick to the polymer backbone).17Chemical and Pharmaceutical Bulletin. Fundamental Investigation of Adsorption Behavior onto Sodium Polystyrene Sulfonate to Potassium Ions and Its Concomitant Drugs in the Digestive Tract This means both charged and uncharged medications are at risk of being soaked up by the resin before they can do their job.
One in vitro study tested 28 commonly co-prescribed drugs and identified 23 potentially new binding interactions with polystyrene sulfonate.18PubMed Central. Binding interactions with sevelamer and polystyrene sulfonate in vitro A clinical trial in healthy volunteers examined the binding between polystyrene sulfonate and amitriptyline, a commonly used antidepressant, and confirmed that the resin can reduce drug absorption enough to potentially blunt effectiveness.19PubMed. Assessing the binding interaction of polystyrene sulfonate with amitriptyline in healthy volunteers: a cross-over design – The BIND study The standard recommendation is to separate SPS dosing from other oral medications by at least three hours, though this is not always practical for patients on complex pill schedules.
How SPS Compares to Newer Potassium Binders
Two newer drugs have entered the market for hyperkalemia: patiromer (brand name Veltassa, approved 2015) and sodium zirconium cyclosilicate, or SZC (brand name Lokelma, approved 2018). Both were developed specifically because the evidence for SPS was weak and the safety profile worrying. They have considerably better clinical trial data behind them.
In head-to-head comparisons, the potassium-lowering ability of SPS and its competitors is often roughly similar. One emergency department study found that both SPS and SZC produced a mean potassium reduction of about 1.1 mEq/L from baseline.20PubMed. Sodium polystyrene sulfonate versus sodium zirconium cyclosilicate for the treatment of hyperkalemia in the emergency department Another trial comparing the two for acute hyperkalemia found nearly identical rates of potassium normalization (around 93-94%), though SZC appeared to reach that goal faster.21European Journal of Hospital Pharmacy. Comparison of sodium zirconium cyclosilicate and sodium polystyrene sulfonate in the treatment of acute hyperkalaemia
Where the newer agents may have a clearer edge is in longer-term treatment and tolerability. A randomized trial in hemodialysis patients found that SZC brought potassium into the normal range within two weeks, compared to six weeks for SPS, and patients rated SZC as more palatable.22PubMed Central. Sodium zirconium cyclosilicate versus sodium polystyrene sulfonate for treatment of hyperkalemia in hemodialysis patients: a randomized clinical trial In a separate study of chronic hemodialysis patients, SPS produced a somewhat greater raw potassium drop than patiromer, but patients scored patiromer higher for tolerability.23Journal of the American Society of Nephrology. Efficacy of Patiromer and Sodium Polystyrene Sulfonate on Potassium Levels in Chronic Hemodialysis Patients Tolerability is not a minor detail here. SPS tastes unpleasant, has a gritty texture, and causes constipation, nausea, and diarrhea frequently enough that many patients struggle with adherence.
The Cost Problem
The biggest reason SPS continues to be prescribed despite everything outlined above is its price. A month of SPS therapy costs a fraction of what patiromer or SZC costs. One cost-utility analysis calculated that a hypothetical alternative drug would need to cost no more than about $11 per daily dose to be considered cost-effective compared to SPS at a standard willingness-to-pay threshold. At $40 per daily dose, which is well below what the newer agents actually cost, the alternative was wildly cost-ineffective by standard metrics.24Clinical Nephrology. Cost-utility analysis of sodium polystyrene sulfonate vs. potential alternatives for chronic hyperkalemia
Real-world data from Sweden echoed this tension. A study of new users of potassium-lowering agents found similar effectiveness and adverse event rates between SPS and the newer binders. However, patients on the newer agents stayed on therapy longer, suggesting better tolerability, which may have downstream effects on outcomes and total healthcare costs.25PubMed Central. Evaluation of the introduction of novel potassium binders in routine care; the Stockholm CREAtinine measurements (SCREAM) project Italian data painted a different picture: total healthcare costs over 12 months were lower with patiromer than with either SZC or SPS, driven by fewer heart-failure-related hospitalizations in the patiromer group.26PubMed. Management of hyperkalaemia in the Italian clinical practice: impact of diverse potassium binders on outcomes and costs in patients with chronic kidney disease and heart failure Whether a cheap drug with higher complication rates or an expensive drug with fewer complications wins on total cost depends on the patient population and the healthcare system doing the math.
Industrial and Environmental Uses of the Polymer
SPS exists outside the pharmacy, too. The polymer itself, poly(sodium 4-styrenesulfonate), is a workhorse material in polymer chemistry and water treatment. It can be synthesized through two distinct routes: free radical polymerization of sodium styrene sulfonate, which produces a linear polymer, and post-sulfonation of polystyrene, which creates a more branched structure with internal sulfone cross-links. The two methods yield products with measurably different physical properties, including different tendencies to interact with water and with dissolved ions.27Polymer International. Effect of structure on solution and interfacial properties of sodium polystyrene sulfonate (NaPSS)
In water treatment, the same ion-exchange property that makes SPS useful for pulling potassium out of the gut can be harnessed to pull heavy metals out of contaminated water. When paired with ultrafiltration membranes, PSS binds dissolved metal ions like lead, copper, and cadmium, forming complexes large enough to be filtered out. Researchers have studied how common dissolved ions found in natural water (sodium, calcium, magnesium) compete with the toxic metals for binding sites on the polymer, since real-world wastewater is never a clean solution of just one contaminant.28Chemical Engineering Journal. Competitive association of cations with poly(sodium 4-styrenesulfonate) (PSS) and heavy metal removal from water by PSS-assisted ultrafiltration The same selectivity questions that matter in the gut, what does the resin actually grab, and what does it leave behind, turn out to matter just as much in an industrial filtration unit.